About the AACR - Leading Discoveries Magazine

Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 54,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 130 countries and territories around the world. Presently, 32% of members live outside the United States and 22% of AACR’s international members are located in countries with emerging economies. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting. In addition, the AACR publishes 10 prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit AACR.org.

AACR Officers

CHIEF EXECUTIVE OFFICER
Margaret Foti, PhD, MD (hc)
American Association for Cancer Research, Philadelphia, Pennsylvania

PRESIDENT
Philip D. Greenberg, MD, FAACR (2023-2024)
The Rona Jaffe Foundation Endowed Chair, Professor & Head, Program in Immunology, Transition Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington

PRESIDENT-ELECT
Patricia M. LoRusso, DO, PhD (hc), FAACR (2023-2024)
Associate Center, Director of Experimental Therapeutics, Director, Early Therapeutics Disease‐Aligned Research Teams, Yale Cancer Center, Professor of Medicine, Yale University, Hamden, Connecticut

IMMEDIATE PAST PRESIDENT
Lisa M. Coussens, PhD, FAACR, FAIO (2023-2024)
Hildegard Lamfrom Endowed Chair in Basic Science, Professor and Chairwoman, Department of Cell, Developmental & Cancer Biology, Deputy Director for Basic & Translational Research, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon

TREASURER
William N. Hait, MD, PhD, FAACR (2022-2025)
Executive Vice President, Chief External Innovation, Medical Safety, and Global Public Health Officer, Johnson & Johnson, New Brunswick, New Jersey

TREASURER-ELECT
Michael A. Caligiuri, MD, FAACR (2022-2025)
President, City of Hope National Medical Center, Deana and Steve Campbell Physician-in-Chief Distinguished Chair, Duarte, California

AACR Directors

Nina Bhardwaj, MD, PhD (2021-2024)
Ward Coleman Chair in Cancer Research, Director of Immunotherapy, Medical Director, Vaccine and Cell Therapy Laboratory, Co-Director, Cancer Immunology Program, The Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai, New York, New York

John M. Carethers, MD (2023-2026)
Vice Chancellor for Health Sciences, Professor of Medicine, University of California, San Diego, La Jolla, California

John D. Carpten, PhD, FAACR (2022-2025)
Director, City of Hope National Medical Center, Director of Beckman Research Institute of City of Hope and Chief Scientific Officer, Irell and Manella Cancer Center Director’s Distinguished Chair, Morgan and Helen Chu Director’s Chair of the Beckman Research Institute, Duarte, California

Christina Curtis, PhD, MSc (2022-2025)
Director, Breast Cancer Translational Research, Co-Director, Molecular Tumor Board, Stanford Cancer Institute, Professor of Medicine, Genetics, and Biomedical Data Science, Stanford University School of Medicine, Stanford, California

Luis A. Diaz, Jr., MD, FAACR (2021-2024)
Grayer Family Chair, Head of the Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York

Susan M. Galbraith, MBBChir, PhD, MRCP, FRCR, FMedSci (2021-2024)
Executive Vice President, Oncology R&D, AstraZeneca, Cambridge, England

Christine M. Lovly, MD, PhD (2023-2026)
Associate Professor of Medicine, Division of Hematology and Oncology, Ingram Professor of Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee

Thomas J. Lynch, Jr., MD (2021-2024)
President and Director, Raisbeck Endowed Chair, Fred Hutchinson Cancer Center, Seattle, Washington

Lisa A. Newman, MD, MPH, FACS, FASCO, FSSO (2021-2024)
Chief, Section of Breast Surgery, NewYork-Presbyterian/Weill Cornell Medical Center, Leader, Multidisciplinary Breast Oncology Programs, NewYork-Presbyterian David H. Koch Center, Weill Cornell Medicine, New York, New York

William Pao, MD, PhD (2022-2025)
Chief Development Officer, Executive Vice President, Pfizer, Inc., New York, New York

Elizabeth A. Platz, ScD, MPH (2023-2026)
Professor and Martin D. Abeloff, MD, Scholar in Cancer Prevention, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

Alice T. Shaw, MD, PhD (2023-2026)
Global Head, Translational Clinical Oncology, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts

Kimberly Stegmaier, MD (2022-2025)
Professor, Pediatrics, Harvard Medical School, Ted Williams Investigator, Dana-Farber Cancer Institute, Boston, Massachusetts

Robert H. Vonderheide, MD, DPhil (2022-2025)
Director, Abramson Cancer Center, Vice Dean and Vice President of Cancer Programs, Perelman School of Medicine and the University of Pennsylvania Health System, Philadelphia, Pennsylvania

Jedd D. Wolchok, MD, PhD, FAACR (2023-2026)
Director, Sandra and Edward Meyer Cancer Center, Professor of Medicine, Weill Cornell Medicine, New York, New York